Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
IMSC,
Implant Sciences' QS-B220 Benchtop Explosives and Narcotics Trace Detector Completes Certification Readiness Testing and Move...
Implant Sciences Corporation (OTCQB: IMSC) (PINKSHEETS: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced that its QS-B220 Explosives and Narcotics Trace Detector has successfully completed the certification readiness testing with the Transportation Security Laboratory ("TSL"), the testing body of the Transportation Security Administration ("TSA"). The B220 is now undergoing the final independent validation testing for TSA qualification for air cargo screening.
"We are pleased to have been informed last week that our B220 system has successfully completed the certification readiness and verification testing and has now been accepted into final validation testing with the TSL. This is a major milestone for the Company. Entering into this final phase of approval gives us great confidence that our desktop B220 explosives trace detection system will be well positioned for adoption in the U.S. and global markets," stated Implant Sciences' President and CEO, Glenn D. Bolduc. "While the next few weeks will be a quiet period during the final stage of testing, we remain confident in our system's performance and are hopeful that we will have good news to report to our shareholders by the end of our fiscal first quarter (ended September 30, 2012). This will put us in good position to capitalize on the December 3, 2012 date for the air cargo industry to comply with the mandates of air cargo screening regulations."
About the Quantum Sniffer™ QS-B220
The QS-B220, introduced in May 2011, is a desktop explosives and narcotics trace detector that uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives, plus narcotic substances. The QS-B220 continues the Implant Sciences tradition of freedom from radioactive materials, low total cost of ownership, and high operational availability.
About Implant Sciences
Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive and narcotics trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and the Company's QS-B220 benchtop explosives and narcotics trace detector has received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.
EXEL,
Meditor must have bought in the recent Secondary priced at 4.25.
Manny
EXEL,
Meditor Group files 13G for 5.3% ownership of EXEL.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8429765
Manny
It is the PDUFA date.
Manny
NAVB,
Think Equity raised their target price of NAVB from 6 to 7.
Stock is currently at 3.94,with a PDUFA date of 9/10/12.
From a poster on IV.
Short term price predictions by ThinkEquity
Most analyst reports are long-term calls. ThinkEquity made some pretty gutsy short-term calls in today's report:
1) We assign more than 90% chance that Lymphoseek could be approved.
2) An approval on September 10th is likely to impact NAVB share price
significantly. We believe the approval will likely create an upside in the range of
20-40% from where NAVB shares are currently trading ... $5/share.
3) Since we think the NAVB share price is likely to appreciate between now and the
PDUFA date, we expect the share price will likely be between $5-6/share
NAVB,
From a poster on IV:
Short term price predictions by ThinkEquity
Most analyst reports are long-term calls. ThinkEquity made some pretty gutsy short-term calls in today's report:
1) We assign more than 90% chance that Lymphoseek could be approved.
2) An approval on September 10th is likely to impact NAVB share price
significantly. We believe the approval will likely create an upside in the range of
20-40% from where NAVB shares are currently trading ... $5/share.
3) Since we think the NAVB share price is likely to appreciate between now and the
PDUFA date, we expect the share price will likely be between $5-6/share
NAVB,
From a poster on IV:
Short term price predictions by ThinkEquity
Most analyst reports are long-term calls. ThinkEquity made some pretty gutsy short-term calls in today's report:
1) We assign more than 90% chance that Lymphoseek could be approved.
2) An approval on September 10th is likely to impact NAVB share price
significantly. We believe the approval will likely create an upside in the range of
20-40% from where NAVB shares are currently trading ... $5/share.
3) Since we think the NAVB share price is likely to appreciate between now and the
PDUFA date, we expect the share price will likely be between $5-6/share
NAVB,
THINKEQUITY RAISES NAVIDEA BIOPHARMACEUTICALS INC < NAVB . A> PRICE TARGET TO $ 7 FROM $ 6 ; RATING BUY
Manny
NAVB,
THINKEQUITY RAISES NAVIDEA BIOPHARMACEUTICALS INC < NAVB . A> PRICE TARGET TO $ 7 FROM $ 6 ; RATING BUY
Manny
From an IV poster:
Friday Close Tute Ownership: 24%
Monday Close Tute Ownership: 24.5%
Tuesday Close Tute Ownership: 26.9%
Wednesday Open Tute Ownership: 31.06%
Here is some info on Institutional holding from an IV poster:
The chart did not copy well.
"We've only just begun.... love that song
Been waiting for the institutions to start reporting and lose some of the short term investors in the process.
Total Shares
New
Increased
Decreased
Activity
Sold Out
106 Increased Institutional Holders
22,239,014 Increased Total Shares Held
Click on the column header links to resort ascending (^) or descending (v).
Owner Name Date Shared Held Change (Shares) Change(%) Value(in 1,000s)
VANGUARD GROUP INC 06/30/2012 11,312,510 3,535,204 45.46 93,441
WELLINGTON MANAGEMENT CO LLP 06/30/2012 9,406,811 3,099,429 49.14 77,700
STATE STREET CORP 06/30/2012 5,897,618 3,195,225 118.24 48,714
BARCLAYS GLOBAL INVESTORS UK HOLDINGS LTD 06/30/2012 5,289,414 495,021 10.33 43,691
BLACKROCK FUND ADVISORS 06/30/2012 5,177,360 529,338 11.39 42,765
FMR LLC 06/30/2012 4,377,073 222,673 5.36 36,155
NORTHERN TRUST CORP 06/30/2012 2,654,407 542,325 25.68 21,925
MORGAN STANLEY 06/30/2012 1,740,395 1,561,429 872.47 14,376
TIAA CREF INVESTMENT MANAGEMENT LLC 06/30/2012 1,070,873 351,010 48.76 8,845
BARCLAYS PLC 06/30/2012 1,055,840 282,525 36.53 8,721
CUPPS CAPITAL MANAGEMENT, LLC 06/30/2012 1,001,772 1,001,772 New 8,275
BANK OF NEW YORK MELLON CORP 06/30/2012 985,731 180,978 22.49 8,142
GEODE CAPITAL MANAGEMENT LLC 06/30/2012 731,475 208,565 39.89 6,042
OXFORD ASSET MANAGEMENT 06/30/2012 713,063 472,102 195.93 5,890
ORBIMED ADVISORS LLC 06/30/2012 600,000 600,000 New 4,956
Also from IV:
ARNA-Someone posted that there were also sales in this period.
Blackrock SOLD 1.3M shares
QVT Financial SOLD 1.2M shares
State of New Jersey Common Pension Fund A SOLD 0.7M shares (sold out)
Bigwig 1 sells, bigwig 2 buys...
Drawing conclusions on this is overreaching.
Lets see what the inst. own. numbers will look like in couple of quarters.
This might be the reason for the move higher.(From IV)
3 institutions reported purchases of over 1 million shares last night
Vangard bought 3.5 million shares.
Morgan Stanley bought 1.5 million shares.
Cupp Capital Management bought 1.01 million shares.
Remember the Belviq approval was on June 27 just 3 days before the end of the quarter.
More to come as the instutions still have one more day to report.
ARNA,
Posted on IV;
Re: ARNA - IMO This was the trigger !!! All job postings were removed from web page!!!
POSTED BEFORE
Could this be the indicator we have been waiting for and that frightened the shorts. As discussed before if multiple partners were announced on a world wide basis then we can be assured that ARENA is not looking at being taken over. BUT if we do not see multiple partners soon then they are probably in takeover talks.
http://www.arenapharm.com/opportunities.aspx
Removing job listing is very significant IMO!
Does anyone know how many job openings were removed?
TIA,
Manny
Is anyone that is using Schwab StreetSmartPro using Direct Access trading during the day or after hours?
It gives you an extra 10 minutes of trading from 9:15 AM to 9:25,and from 4:05 to 4:15,when you can't use StreetSmart Pro.
The agreement you have to sign to trade seems scary.
TIA,
Manny
TLON,
Talon Therapeutics Looks Undervalued Following FDA's Surprise Early Approval Press Release: BioMedReports – 55 minutes ago
By Brian Wilson, Contributor
Shareholders of Talon Therapeutics ( TLON) saw a pleasant surprise on August 9th when the FDA approved the company`s flagship product, Marqibo, three days earlier than expected.
The initial decision date under the PDUFA was on August 12th, which was set after an initial three month delay that was announced back in April. We can now put all the drama over Marqibo`s NDA aside; however, because the FDA has given Talon the green light it`s been waiting on for years. The bears that were selling in anticipation of a rejection were indeed wrong.
Marqibo is a targeted version of a generic chemotherapeutic agent known as vincristine, which has been around for nearly fifty years. This has diminished investor excitement over Marqibo`s development, and investors who`ve followed the drug in the past may remember the FDA rejection in 2005 for the treatment of relapsed non-Hodgkin`s lymphoma that allowed Talon to license Marqibo on the cheap.
Despite its history, and a very mixed advisory panel vote back in March (with 7 in favor of approval and 4 again), Marqibo is now set to enter the Acute Lymphoblastic Leukemia market. Competing drugs for Acute Lymphoblastic Leukemia include a large number of candidates, but two that are mentioned in an overview of the disease at the Mayo Clinic website are Novartis` ( NVS) Gleevec and Bristol-Meyers` ( BMY) Sprycel, both of which are used for other types of cancer as well.
Talon`s Marqibo is special, however, since it was developed for use in older adults (aged 60 or older). This demographic has been difficult for conventional ALL therapies, which include radiation and chemotherapy which can cause complications quite easily in older patients. Comments by Talon indicate that the company is expecting to reach approximately 2,000 US patients per year with the current FDA approval.
There is also hope that Marqibo will be able to tap into the ~2 million patient market that generic vincristine sells to. This may be possible due to Marqibo`s ability to deliver a dosage of vincristine itself that is much more potent while having the same safety profile as the original. Since chemotherapy leaves patients especially frail, this is a vital aspect of the treatment`s success. It seems that patient`s great tolerance is paving the way for Marqibo to finally succeed.
We are also going to see an NDA to bring Marqibo to market for front-line treatment of non-Hodgkin`s lymphoma after additional phase III data is collected and compiled to address issues brought up in 2005, when it was rejected.
Even if Talon`s penny-stock status may seem daunting, there is substantial value that is locked into Marqibo that apparently isn`t recognized by main stream investors. It is certainly optimistic to say that a very significant portion of vincrinstine`s enormous pool of sales could be quickly given to a replacement drug that barely made it past FDA approval right off the bat, but I also want to point out that it wouldn`t take much market penetration to bring this 21.5 million dollar company to profitability. Remember that approval down the road in non-Hodgkin`s lymphoma treatment could also weigh in quite heavily on the company`s value.
Ultimately, it would seem likely that TLON shares will see higher ground as Marqibo finally gets brought to cancer patients. Speculators might want to play the eventual NDA on non-Hodgkin`s lymphoma treatment too. The full report on TLON including Technical Analysis is available at:
http://www.biomedreports.com/20120810101618/talon-therapeutics-looks-undervalued-following-fda-approval.html
Healthcare investors and Biotech traders interested in accessing BioMedReports` new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades and see upcoming catalysts can go to: http://biomedreports.com/fdacal.html
Follow Us
News developments and live healthcare sector updates are available constantly via twitter at: http://twitter.com/BioMedReports
####
About BioMedReports.Com
BioMedReports is a news and research portal covering financial biomedical news and the entire Healthcare Sector of the market. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies. BioMedReports sells a premium product for subscribers and full disclosures and information about the stocks and news mentioned in this news release is available at BioMedReports.Com
Found on IV:
Nigeria Oil Output Rises to Record on Improved Security
Lets hope this trend continue so the Nigeria discount can be reduced.
http://www.bloomberg.com/news/2012-08-02/nigeria-oil-output-rises-to-record-on-improved-security-1-.html
Crude oil output in Nigeria, Africa’s biggest producer, reached an “all-time high” after security improved in the southern oil-producing Niger River delta region, Andrew Yakubu, group managing director of the Nigerian National Petroleum Corp., said.
Total production rose yesterday to 2.7 million barrels a day from 2.4 million barrels, he said in an e-mailed statement today from Abuja, the capital.
“The security measures put in place by the federal government in the Niger Delta region was beginning to yield positive results,” Yakubu, who was appointed to the job in June, said in the statement. Security along oil pipelines and production facilities has been restored, he said.
Energy companies have stepped up production as attacks on installations in the delta declined following a 2009 government amnesty for militants in the region fighting for a greater share of oil resources. Attacks by armed groups cut more than 28 percent of the country’s output between 2006 and 2009, according to data compiled by Bloomberg.
At least 90 percent of the country’s oil is pumped by the state oil company, also known as NNPC, in joint ventures with Royal Dutch Shell Plc (RDSA), Exxon Mobil Corp., Chevron Corp. (CVX), Total SA (FP) and Eni SpA. (ENI)
Nigeria depends on oil exports for more than 80 percent of government revenue and 95 percent of foreign-exchange income. The West African nation earned $196 billion from oil and gas shipments in the four years through 2010, according to the National Bureau of Statistics.
VHC,
From a poster on IV:
Re: Timing of Settlements
Eric,
Further to your point, I noticed when reading the transcript from the most recent Markman hearing, that Mr. Ruffin Cordell, Esq, of the law firm Fish & RIchardson, who was representing Avaya, told the court that his firm also represented Mitel and confirmed that Mitel settled the night before the Markman hearing.
If the same lawyers represented Mitel and Avaya, my guess is that would make your forecast for another settlement soon even more likely.
It couldn't happen to a more deserving company.(Knight going bankrupt)
I remember when I was new at this trading,they would STEAL money from me on executions.
Manny
From Company site: "VirnetX Receives Markman Order In Patent Infringement Action Against Avaya and Siemens"
VirnetX Receives Markman Order In Patent Infringement Action Against Avaya and Siemens
Posted on 02. Aug, 2012 by admin in Press Releases
Court Stands by Original Ruling
ZEPHYR COVE, Nevada – August 2, 2012 – VirnetX Holding Corporation (NYSE MKT: VHC), an Internet security software and technology company, announced today that on August 1, 2012, the United States District Court for the Eastern District of Texas, Tyler Division, issued its patent claim construction, or “Markman” Order (“Markman Order”) in the ongoing patent infringement action between VirnetX Inc. (“VirnetX”) and Avaya Inc. and Siemens Enterprise Communications GmBH & Co. KG; Siemens Enterprise Communications, Inc.
In a Markman ruling, a district court hearing a patent infringement case interprets and rules on the scope and meaning of disputed patent claim language regarding the patents in suit. A Markman decision is often a significant factor in the progress and outcome of patent infringement litigation.
In the recently issued Markman Order, the Court denied the request by the defendants to change the interpretation of some of the claim terms that were in dispute in the litigation, leaving them unchanged from what was previously adopted by the court in the Markman ruling in its other ongoing infringement action against Cisco, Apple and NEC.
“We are extremely pleased with the Court’s Markman Order. We remain confident in the merits of our complaint against Avaya and Siemens” said Kendall Larsen, VirnetX President and CEO. “While the outcome of this and any legal matter is unpredictable, we believe the Court’s Markman Order is another significant step towards the successful resolution of this litigation.”
CIGX,
Gilford Securities:Initiates with a Buy .Calls Star Scientific - A Disruptive Science?
The report is 13 pages long and very positive from an investment banker that intends to provide services for Star.
In the normal course of business, Gilford Securities seeks to perform investment banking and other services for various companies and to receive compensation in connection with such services. As such, Gilford Securities intends to seek compensation for investment banking services from the subject company in the next three months.
The analyst and family members own shares of the subject company.
INVESTMENT SUMMARY
Star Scientific was a controversial story for many years primarily because of litigation against Reynolds Tobacco (now Reynolds American – RAI – 46.27). Star was hopeful of winning significant litigation damage awards but that process is fraught with delays. Star now appears within weeks or months of enormously positive accomplishments in as many as four major arenas.
1) Explosive growth of Star’s Anti-Inflammatory Dietary Supplement Anatabloc, 2) Worldwide tobacco industry licensing revenue streams, 3) A potential settlement from Reynolds, and 4) Pharmaceutical industry partnerships A fifth possibility, potentially most important of all but not likely until the spring of 2013, will be results of clinical treatment for Alzheimer’s disease.
Each one of the five above has the potential to produce hundreds of millions of dollars of revenue and significant profit over the next several years – beginning later this year. Instead of being a mere single litigation speculation, Star’s Anatabine technology and its potential capability for controlling inflammation could become a truly “disruptive science”, possibly with dramatic impact upon several inflammation-related autoimmune diseases. (See sections “The Anatabine” and “Inflammation” on pages 3 & 4.)
One example of Star’s near-term potential: We believe it possible that a release of a Johns Hopkins University School of Medicine report describing positive test results from humans for treatment of thyroid diseases using Star’s Anatabine technology could cause sales of Star’s Anatabloc anti-inflammatory tablet (now on the market over-the-counter) to skyrocket from virtually nothing today to an annual run-rate over $400 million (with profit of $200 million or $1.00 per share) in 2013. (See “2013 Estimates” page 6.) Test results from Hopkins are expected to be released this third (September) quarter. We hope August.
CIGX,
Gilford Securities:Initiates with a Buy .Calls Star Scientific - A Disruptive Science?
The report is 13 pages long and very positive from an investment banker that intends to provide services for Star.
In the normal course of business, Gilford Securities seeks to perform investment banking and other services for various companies and to receive compensation in connection with such services. As such, Gilford Securities intends to seek compensation for investment banking services from the subject company in the next three months.
The analyst and family members own shares of the subject company.
INVESTMENT SUMMARY
Star Scientific was a controversial story for many years primarily because of litigation against Reynolds Tobacco (now Reynolds American – RAI – 46.27). Star was hopeful of winning significant litigation damage awards but that process is fraught with delays. Star now appears within weeks or months of enormously positive accomplishments in as many as four major arenas.
1) Explosive growth of Star’s Anti-Inflammatory Dietary Supplement Anatabloc, 2) Worldwide tobacco industry licensing revenue streams, 3) A potential settlement from Reynolds, and 4) Pharmaceutical industry partnerships A fifth possibility, potentially most important of all but not likely until the spring of 2013, will be results of clinical treatment for Alzheimer’s disease.
Each one of the five above has the potential to produce hundreds of millions of dollars of revenue and significant profit over the next several years – beginning later this year. Instead of being a mere single litigation speculation, Star’s Anatabine technology and its potential capability for controlling inflammation could become a truly “disruptive science”, possibly with dramatic impact upon several inflammation-related autoimmune diseases. (See sections “The Anatabine” and “Inflammation” on pages 3 & 4.)
One example of Star’s near-term potential: We believe it possible that a release of a Johns Hopkins University School of Medicine report describing positive test results from humans for treatment of thyroid diseases using Star’s Anatabine technology could cause sales of Star’s Anatabloc anti-inflammatory tablet (now on the market over-the-counter) to skyrocket from virtually nothing today to an annual run-rate over $400 million (with profit of $200 million or $1.00 per share) in 2013. (See “2013 Estimates” page 6.) Test results from Hopkins are expected to be released this third (September) quarter. We hope August.
NAVB,
KNIGHT fiasco includes NAVB
http://markets.nyx.com/nyse/trader-updates/view/11183
open the 'Affected Stocks' attachment and see NAVB on line 94
Manny
All I can say is,some of the major posters on the IV NAVB board were absolutely giddy with excitement at being able to add near the lows today.
They believe this is a Short attack.
I bought some in the low 3's myself.
I hope they are right. 3.50 Bid right now.
Manny
Do you know that GNC offers 20% off for Gold Card members?
The Gold card is 15 dollars for the year,and you can get the 20% immediately.
After that you can get 20% off on anything available in GNC in the first week of every month.
Manny
VHC,
Posted on IV:
VirnetX Holding Corp. Named as Secure Communications Leader by Independent Research Paper
Report details Significant Opportunity in 4G Wireless 07/31 09:00 AM
LOS ANGELES, July 31, 2012 /PRNewswire/ -- An independent equity research report for VirnetX Holding Corporation (VHC:$24.29,$1.62,7.15%) is now available at www.vhcreport.com. San Gabriel Fund is releasing the 96-page white paper entitled "Enabling Advanced Communications: How VirnetX Will Profit From Next-Gen Networks" proclaims VirnetX (VHC:$24.29,$1.62,7.15%) owns technology that is central to the next-generation of telecommunications networks. In the report, author J.P. Moreno describes significant revenue opportunities for VirnetX (VHC:$24.29,$1.62,7.15%) and provides a conservative sum-of-parts analysis. The researcher analyzes several key components of VirnetX (VHC:$24.29,$1.62,7.15%) including the company's history, technology, patent portfolio, legal proceedings, and market opportunities. The report offers detailed analysis on how VirnetX (VHC:$24.29,$1.62,7.15%) technology will enable global real-time communications and how the company will monetize its intellectual property going forward.
Key highlights:
History of VirnetX (VHC:$24.29,$1.62,7.15%) 's origins tracing back to Science Applications International Corporation (SAIC), a Fortune 500 company, and PASW Inc., a developer of Internet Protocol version 4 (IPv4). VirnetX (VHC:$24.29,$1.62,7.15%) emerged as a publicly traded company with significant experience and expertise in developing security solutions utilizing the domain name system (DNS). Combined with the assignment rights for two Class "B" Internet Address Blocks, VirnetX (VHC:$24.29,$1.62,7.15%) is in a unique position to enable secure communications for virtually all next-generation devices.
Thorough examination of the company's intellectual property, including patents declared "essential" to Advanced 4G wireless standards (e.g. LTE-Advanced). Detailed analysis of the technology and next-generation networks demonstrates there are no feasible alternatives or workarounds to using VirnetX (VHC:$24.29,$1.62,7.15%) 's inventions. The VirnetX (VHC:$24.29,$1.62,7.15%) patent portfolio will also be utilized by products and services that are not related to wireless standards. Therefore, exposure to FRAND obligations will be limited.
Chronicling past and present litigation proceedings to identify key events and timelines. Litigation settlements and licensing agreements have been forged with Microsoft Corp. and Aastra USA, Inc. (A settlement and licensing agreement between VirnetX (VHC:$24.29,$1.62,7.15%) and Mitel Networks Corp. was announced after publication of this report.)
Technology overview that highlights the evolution of next-generation networks. There will be a proliferation of devices that utilize VirnetX (VHC:$24.29,$1.62,7.15%) 's technology, including mobile phones, tablets, laptop computers, network appliances, servers, routers, small cells and other infrastructure equipment. Additionally, other products will be connected through modules that enable televisions, cameras, blu-ray players, cars, homes, and even office buildings to utilize the secure communications technology of VirnetX (VHC:$24.29,$1.62,7.15%) .
Monetization model that details multiple revenue streams including 4G product licensing and secure domain services licensing.
About J.P. Moreno:
J.P. Moreno is an independent researcher and professional engineer with both bachelor's and master's degrees. The report reflects over a decade of intellectual property investment research and networking experience. For further information including disclaimers please see report. Additional information may be requested by email: info@vhcreport.com
About San Gabriel Fund:
San Gabriel Fund, LLC is a private investment fund headquartered in Los Angeles, California.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of any securities of VHC in any state in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
Disclaimer:
This White Paper constitutes private research and is for informational purposes only and the opinions of the author herein are strictly intended for reading only by those persons to whom it is or has been directly released by the author. The data and analysis contained herein are provided "as is" and without representation or warranty of any kind, either expressed or implied. San Gabriel Fund and the author make no representation or claim guaranteeing the accuracy of any opinions or information. Neither San Gabriel Fund, the author, nor his agents nor any third party data provider, shall have any liability of any nature whatsoever for any loss of whatever nature sustained by any person or entity which has relied on the information or analysis contained in this publication. You should always obtain reliable current information and perform your own due diligence before investing or trading. You bear responsibility for your own investment research and trading decisions and this publication does not serve as a substitute or endorsement for either and the author disclaims all responsibility and liability in connection therewith. Always seek the advice of a qualified securities professional before making any investment. This is not an investment recommendation and the data, and analysis based upon the data, may be subject to error despite best efforts. All opinions expressed herein are subject to change without notice.
Section 17(b) of the Securities Act of 1933 requires that any person that uses the mails to publish, give publicity to, or circulate any publication or communication that describes a security in return for consideration received or to be received directly or indirectly from an issuer, underwriter, or dealer, must fully disclose the type of consideration (i.e. cash, free trading stock, restricted stock, stock options, stock warrants) and the specific amount of the consideration. In connection therewith, San Gabriel Fund, LLC and/or J. P. Moreno have received the following consideration and/or otherwise has ownership in the securities of the Profiled Company, as follows:
(a) San Gabriel Fund, LLC and a related fund own approximately 2 million shares of VirnetX Holding Corp. (VHC:$24.29,$1.62,7.15%) common stock. San Gabriel Fund, LLC is not receiving any compensation from VirnetX (VHC:$24.29,$1.62,7.15%) in connection with the release and/or dissemination of this report.
(b) J.P. Moreno independently prepared this report. However, after the report was completed, San Gabriel Fund, LLC paid J.P. Moreno$10, 000 for the right to view the report and publish its findings. J.P. Moreno also received compensation from others in connection with their right to view this report. J.P. Moreno is not receiving any compensation from VirnetX (VHC:$24.29,$1.62,7.15%) in connection with the release and/or dissemination of this report.
SOURCE San Gabriel Fund
NAVB,
It is interesting that NAVB has sold off right after Platinum-Montaur agreed to loan the company up to 50 million dollars.
On Friday,Platinum Montaur filed a 13G showing that they owned 9.9% of the company's shares outstanding and over 30% if you include warrants and convertibles..
I believe this 13G filing now gives them time to sell shares of NAVB so they can have the 50 million dollars available for the loan .
I will bet that in the next 13G filing those NAVB sales by Platinum-Montaur will show up around this time period.
IMHO,
Manny
NAVB,
I have a feeling that Platinum-Montaur is SELLING NAVB shares now that they filed their 13G,which gives them time before they have to reveal their selling right after last week's 13G.
I think they were hoping that the stock would move higher on their PR of loaning NAVB up to 50 million dollars.
They are probably selling NAVB shares to have the money for the loan.
Manny
The 95,492,330 shares is outstanding shares not including warrants or convertibles,as it says in the Form 13G.
(a)
Amount Beneficially Owned: 9,539,684 shares of common stock
(b)
Percent of class: 9.99%
Manny
NAVB,
Platinum Montaur files a 13G showing it owns 9.9% of the company's shares.
If you want to do the math,with convertibles and warrants they own about 39% of the company.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8383773
Platinum Partners Value Arbitrage Fund L.P.
(a)
Amount Beneficially Owned: 9,539,684 shares of common stock
(b)
Percent of class: 9.99%
(c)
Number of shares as to which such person has:
(i) Sole power to vote or to direct the vote: 0
(ii) Shared power to vote or to direct the vote: 9,539,684
(iii) Sole power to dispose or to direct the disposition of: 0
(iv) Shared power to dispose or to direct the disposition of: 9,539,684
As of April 2, 2012, the Reporting Persons collectively beneficially owned 9,539,684 shares of Common Stock. The shares of Common Stock beneficially owned by the Reporting Persons represent 9.99% percent of the outstanding shares of Common Stock. The 9.99% ownership calculation was based on the 95,492,330 shares of Common Stock reported by the Issuer as being outstanding as of February 17, 2012 on Form 10-K filed by the Issuer with the Securities and Exchange Commission on March 6, 2012.
The number of shares of Common Stock beneficially owned by the Reporting Persons excludes the following to the extent that the conversion and/or exercise thereof would be prohibited by the 9.99% Blocker (as defined below), all of which are directly owned by Platinum-Montaur Life Sciences, LLC:
?
6,000,000 shares of Common Stock issuable upon exercise of a Series W Warrant issued on December 26, 2007, as amended (the “Series W Warrant”);
?
8,333,333 shares of Common Stock issuable upon exercise of a Series X Warrant issued on April 16, 2008, as amended (the “Series X Warrant”);
?
2,400,000 shares of Common Stock issuable upon exercise of a Series AA Warrant issued on July 24, 2009 (the “Series AA Warrant”); and
?
29,701,410 shares of Common Stock issuable upon conversion of 9,083 shares of Series B Convertible Preferred Stock (the “Preferred Stock”).
NAVB,
Platinum Montaur files a 13G showing it owns 9.9% of the company's shares.
If you want to do the math,with convertibles and warrants they own about 39% of the company.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8383773
Platinum Partners Value Arbitrage Fund L.P.
(a)
Amount Beneficially Owned: 9,539,684 shares of common stock
(b)
Percent of class: 9.99%
(c)
Number of shares as to which such person has:
(i) Sole power to vote or to direct the vote: 0
(ii) Shared power to vote or to direct the vote: 9,539,684
(iii) Sole power to dispose or to direct the disposition of: 0
(iv) Shared power to dispose or to direct the disposition of: 9,539,684
As of April 2, 2012, the Reporting Persons collectively beneficially owned 9,539,684 shares of Common Stock. The shares of Common Stock beneficially owned by the Reporting Persons represent 9.99% percent of the outstanding shares of Common Stock. The 9.99% ownership calculation was based on the 95,492,330 shares of Common Stock reported by the Issuer as being outstanding as of February 17, 2012 on Form 10-K filed by the Issuer with the Securities and Exchange Commission on March 6, 2012.
The number of shares of Common Stock beneficially owned by the Reporting Persons excludes the following to the extent that the conversion and/or exercise thereof would be prohibited by the 9.99% Blocker (as defined below), all of which are directly owned by Platinum-Montaur Life Sciences, LLC:
?
6,000,000 shares of Common Stock issuable upon exercise of a Series W Warrant issued on December 26, 2007, as amended (the “Series W Warrant”);
?
8,333,333 shares of Common Stock issuable upon exercise of a Series X Warrant issued on April 16, 2008, as amended (the “Series X Warrant”);
?
2,400,000 shares of Common Stock issuable upon exercise of a Series AA Warrant issued on July 24, 2009 (the “Series AA Warrant”); and
?
29,701,410 shares of Common Stock issuable upon conversion of 9,083 shares of Series B Convertible Preferred Stock (the “Preferred Stock”).
VHC,
I am sure you don't know a thing about VHC technology.
I have been following it a long time,and I still don't understand all the nuances.
There are some brilliant posters on the IV VHC message board who believe VHC will succeed against AAPL,CSCO and the other players.
These Hedge Funds have a lot of money,and I think they passed on the negative info to someone who knows Herb Greenberg,who helped them in their very underwater Short.
I can't believe CNBC is letting this guy broadcast this stuff.
Manny
VHC,
VHC is being targeted by powerful Short hedge Funds with the probable help of Cramer and Herb Greenberg.
I have stopped watching CNBC because of Greenberg's involvement in this decline.
It is complicated stuff,but Guilford Securities reiterated a Buy with a target of 65.
News Breaks
July 27, 2012
08:27 EDT VHC
theflyonthewall.com: Firm says inaccurate statements have been made about VirnetX
Gilford Securities believes that several inaccurate statements regarding VirnetX (VHC) have surfaced in recent weeks. The firm doesn't believe that an ITC judge has decided to dismiss the company's case, and it doesn't expect the case to be delayed for 16-24 months as some have suggested. Furthermore, Gilford doesn't believe that a delay in the case necessarily indicates that a potential resolution between Apple (AAPL) and VirnetX would be delayed by one or two years. Gilford doesn't think that the recent Markman hearing raised any new unfavorable issues for VirnetX, and the firm doesn't see recent stock pledges by its CEO as problematic. Finally, Gilford thinks that VrinetX can potentially recover damages from other companies, and it reiterates a $65 target and Buy rating on the stock in a note to investors this morning. :theflyonthewall.com
This is from the Motley Fool.
On July 26, 2012, at 12:04 AM, eldoctoro wrote: Rich,
IMHO the ITC delay may have had a very small part to play in VHC precipitous drop. Many on the VHC Yahoo and IV board however believe the sell off was a carefully orchestrated bear raid designed to mitigate the massive potential losses to short sellers with 40% of float short position. First Jim Cramer states on national TV that he now believes in VHC and gives a BUY BUY BUY! Then 2 days later Herb Greenberg posts a VHC hit piece (Hidden Risk of VHC) in which he not only suggests the recent settlements between VHC and Mitel and Aastra were of little to no monetary valueme AND further that CEO Ken Larsen's 8+ million shares may be at risk of a margin call (think Green Mountain Coffee) and he could bee forced to sell millions of shares of VHC.
FWIW...I and many others have contacted CNBC, the SEC and our Senators and Congressmen and asked for an investigation.
This is not the first time Greenberg has published hit pieces based on falsehoods and intentional bias (he has no clue what the terms of settlements with Mitel and Aastra are). Greenberg's history seems to be 'trash now'..'due diligence later'. What a joke he must be with legitimate analysts laughing behind his back! all IMHO.
NAVB,
Platinum-Montaur owns approximately 39% Of NAVB if you include warrants,so it is in their interest for NAVB to succeed.
Manny
NAVB,
Platinum-Montaur owns approximately 39% Of NAVB if you include warrants,so it is in their interest for NAVB to succeed.
Manny
NAVB,
Gets funding from its biggest shareholder
(Navidea Biopharmaceuticals Announces $50 Million Credit Facility with Platinum-Montaur Life Sciences -Transaction provides flexible financial resources to fund short- and long-term development and growth plans-)
DUBLIN, Ohio, Jul 26, 2012 (BUSINESS WIRE) -- Navidea Biopharmaceuticals, Inc.
(NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic
radiopharmaceuticals, today announced that Platinum-Montaur Life Sciences, LLC
(Montaur) will provide Navidea a credit facility of up to $50 million. This
transaction provides the Company with significant, yet flexible, financial
resources to fund its development and growth plans. No draws are currently
planned in connection with entering into this facility.
Under the terms of the transaction, Montaur has committed to extend up to $15
million in debt, which is available immediately, to the Company at a prime-based
interest rate currently at approximately 10 percent per annum. Montaur has
committed an additional $20 million upon approval of Lymphoseek on consistent
terms, with yet an additional $15 million potentially available on terms to be
negotiated. No conversion features or warrants are associated with the facility.
Navidea is currently awaiting a response from the FDA on a New Drug Application
that w as submitted for Lymphoseek(R), its novel
radiopharmaceutical imaging agent intended for use by surgeons in lymphatic
mapping procedures associated with solid tumor cancers. Additionally, the
Company's pipeline includes the ongoing development
of a number of diagnostic agents: AZD4694, a beta amyloid imaging agent for
Alzheimer's Disease; and RIGScan, a radio-labeled
antibody diagnostic being studied in colorectal cancer.
Michael Goldberg, M.D., Principal, Montaur Capital Partners, LLC and Portfolio
Manager of Montaur, said, "Navidea has been, and
continues to represent, an excellent investment for Montaur. Our commitment to
extend Navidea a non-dilutive credit facility is yet another sign of our
confidence in Navidea, its expanding product pipeline and its management. We
believe this transaction will support Navidea's
business and growth plans well through the launch period for Lymphoseek, by
providing readily-available capital to support their business and pursue other
desirable products and license opportunities that fit the
Company's aggressive strategy of pipeline
development."
Mark J. Pykett, V.M.D., Ph.D., Navidea's President
and CEO said, "We are energized by
Montaur's significant financial commitment and
confidence in Navidea's future. This transaction will
provide us considerable flexibility to continue funding our growth as needed.
Our financial partnership with Montaur has afforded us access to potential
resources to confidently implement our plans to deepen our portfolio and advance
our business as a leader in precision diagnostics."
About Navidea Biopharmaceuticals, Inc.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company
focused on the development and commercialization of precision diagnostics and
radiopharmaceutical agents. Navidea is actively developing three
radiopharmaceutical agent platforms - Lymphoseek(R),
AZD4694 and RIGScan(TM) - to help identify the si tes and pathways
of undetected disease and enable better diagnostic accuracy, clinical
decision-making and ultimately patient care.
Navidea's strategy is to deliver superior growth and
shareholder return by bringing to market novel radiopharmaceutical agents and
advancing the Company's pipeline through selective
acquisitions, global partnering and commercialization efforts. For more
information, please visit www.navidea.com.
NAVB,
Gets funding from its biggest shareholder
(Navidea Biopharmaceuticals Announces $50 Million Credit Facility with Platinum-Montaur Life Sciences -Transaction provides flexible financial resources to fund short- and long-term development and growth plans-)
DUBLIN, Ohio, Jul 26, 2012 (BUSINESS WIRE) -- Navidea Biopharmaceuticals, Inc.
(NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic
radiopharmaceuticals, today announced that Platinum-Montaur Life Sciences, LLC
(Montaur) will provide Navidea a credit facility of up to $50 million. This
transaction provides the Company with significant, yet flexible, financial
resources to fund its development and growth plans. No draws are currently
planned in connection with entering into this facility.
Under the terms of the transaction, Montaur has committed to extend up to $15
million in debt, which is available immediately, to the Company at a prime-based
interest rate currently at approximately 10 percent per annum. Montaur has
committed an additional $20 million upon approval of Lymphoseek on consistent
terms, with yet an additional $15 million potentially available on terms to be
negotiated. No conversion features or warrants are associated with the facility.
Navidea is currently awaiting a response from the FDA on a New Drug Application
that w as submitted for Lymphoseek(R), its novel
radiopharmaceutical imaging agent intended for use by surgeons in lymphatic
mapping procedures associated with solid tumor cancers. Additionally, the
Company's pipeline includes the ongoing development
of a number of diagnostic agents: AZD4694, a beta amyloid imaging agent for
Alzheimer's Disease; and RIGScan, a radio-labeled
antibody diagnostic being studied in colorectal cancer.
Michael Goldberg, M.D., Principal, Montaur Capital Partners, LLC and Portfolio
Manager of Montaur, said, "Navidea has been, and
continues to represent, an excellent investment for Montaur. Our commitment to
extend Navidea a non-dilutive credit facility is yet another sign of our
confidence in Navidea, its expanding product pipeline and its management. We
believe this transaction will support Navidea's
business and growth plans well through the launch period for Lymphoseek, by
providing readily-available capital to support their business and pursue other
desirable products and license opportunities that fit the
Company's aggressive strategy of pipeline
development."
Mark J. Pykett, V.M.D., Ph.D., Navidea's President
and CEO said, "We are energized by
Montaur's significant financial commitment and
confidence in Navidea's future. This transaction will
provide us considerable flexibility to continue funding our growth as needed.
Our financial partnership with Montaur has afforded us access to potential
resources to confidently implement our plans to deepen our portfolio and advance
our business as a leader in precision diagnostics."
About Navidea Biopharmaceuticals, Inc.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company
focused on the development and commercialization of precision diagnostics and
radiopharmaceutical agents. Navidea is actively developing three
radiopharmaceutical agent platforms - Lymphoseek(R),
AZD4694 and RIGScan(TM) - to help identify the si tes and pathways
of undetected disease and enable better diagnostic accuracy, clinical
decision-making and ultimately patient care.
Navidea's strategy is to deliver superior growth and
shareholder return by bringing to market novel radiopharmaceutical agents and
advancing the Company's pipeline through selective
acquisitions, global partnering and commercialization efforts. For more
information, please visit www.navidea.com.
VHC,
Posted on IV:
The Fly: "VirnetX feels that this does not have any impact on the merits of our complaint with the ITC or the two cases pending.."
News Breaks
July 24, 2012
18:15 EDT AAPL, VHC
theflyonthewall.com: VirnetX to appeal to International Trade Comission in complaint against Apple
VirnetX Holding (VHC) announced that on July 18 the Administrative Law Judge assigned to investigate the complaint, filed by its wholly-owned subsidiary, VirnetX, with the U.S. International Trade Commission, or ITC, against Apple (AAPL), has identified a procedural discrepancy with the complaint filed by VirnetX that will impact the scheduling of the investigation. VirnetX disagrees with this finding and intends to appeal and/or re-file the complaint with the ITC as necessary. The Company feels that this does not have any impact on the merits of our complaint with the ITC or the two cases pending in the Eastern District of Texas. :theflyont